Tysabri泰吉利

Tysabri

natalizumab

Manufacturer:

Biogen

Distributor:

Zuellig
/
Agencia Lei Va Hong

Marketer:

Eisai
Concise Prescribing Info
Contents
Natalizumab
Indications/Uses
Highly active relapsing remitting multiple sclerosis.
Dosage/Direction for Use
Adult 300 mg IV infusion once every 4 wk.
Contraindications
Hypersensitivity. Progressive multifocal leukoencephalopathy (PML). Immunocompromised patients. Combination w/ β-interferons or glatiramer acetate. Known active malignancies except cutaneous basal cell carcinoma. Lactation. Childn & adolescent <18 yr.
Special Precautions
Infections. Increased risk of PML. Concurrent or prior treatment w/ immunosuppressants. Patients on a controlled Na diet. May affect ability to drive or operate machinery. Pregnancy.
Adverse Reactions
Serious infections (unexplained fever, severe diarrhea, shortness of breath, prolonged dizziness, headache, weight loss, listlessness), allergy during or shortly after infusion (hives, swelling of the face, lips or tongue; difficulty breathing; chest pain or discomfort; increased or decreased BP), liver problem (jaundice, unusual darkening of urine). UTI, sore throat & runny or blocked up nose, shivering, hives, headache, dizziness, nausea, vomiting, joint pain, fever, tiredness. Serious infections.
Drug Interactions
β-interferons or glatiramer acetate. Immunosuppressive drugs eg, mitoxantrone or cyclophosphamide.
MIMS Class
ATC Classification
L04AA23 - natalizumab ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Presentation/Packing
Form
Tysabri conc for soln for infusion 20 mg/mL
Packing/Price
15 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in